Onco Wiki - Régimen

CHOEP (cyclophosphamide + doxorubicin + vincristine + etoposide + prednisone), 6 cycles

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.

Fuente YAML: registro completo

ComponentesDRUG-CYCLOPHOSPHAMIDE DRUG-DOXORUBICIN DRUG-VINCRISTINE DRUG-ETOPOSIDE DRUG-PREDNISONE
IDREG-CHOEP
TipoEsquema terapéutico
Situaciónpending_clinical_signoff
EnfermedadesNinguna declarada
FuentesSRC-NCCN-BCELL-2025

Notas

Used for fit younger PTCL NOS / AITL when CD30 negative or brentuximab not accessible. CHOEP (with etoposide) showed improvement over CHOP in younger T-cell patients per Nordic data. 6 cycles + autoSCT consolidation in fit transplant-eligible — practice standard for PTCL/AITL despite limited RCT evidence.

Evidence for specific statements

These citations cover only the statements and scopes shown. They do not establish clinical approval of this record.

CHOEP21 monitoring follows its own 21-day regimen and drug-specific toxicity assessment. It must not inherit CD20-positive DLBCL, double-hit, IPI, CNS-IPI or anti-CD20-specific checkpoints from R-CHOP. Neuropathy assessment concerns vincristine; etoposide administrations occur on days 1-3. Count-based delay and growth-factor decisions require CHOEP-specific clinical review.

Regimen-specific monitoring only; not whole-record dosing, efficacy, eligibility, transplant or clinical approval.

SRC-EVIQ-CHOEP21-630

eviQ 630 Treatment schedule, Clinical information, Dose modifications/Haematological toxicity and Pre-treatment assessment.

Utilizado por

Indicación

Seguimiento

Cuidado de apoyo